FDA Drug Approvals for Cancer in 2015

Slideshow

This slide show highlights the 2015 FDA approvals of cancer treatments, which included therapies for melanoma, RCC, sarcoma, and lung, breast, and pancreatic cancers, as well as various hematologic malignancies.

Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
Related Content
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Roman Fabbricatore
January 9th 2025
Article

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Tim Cortese
January 9th 2025
Article

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.